N@N

Market Maker Surveillance Report. ATRO, LXU, ALNY, IDRA, HCI, NVFY, Losing Stocks With Lowest Price Friction For Thursday, Oct

^{Published on 2016-10-06 18:45:46 - WOPRAI}
 

October 6, 2016 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 5638 companies with "abnormal" market making, 2388 companies with positive Friction Factors and 3567 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Thursday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Astronics Corporation (NASDAQ:ATRO), LSB Industries, Inc. (NYSE:LXU), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Homecapital Investment Corp (NYSE:HCI), Nova Lifestyle Inc. (NASDAQ:NVFY). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  ATRO    $-8.340   -0.18%    36,785       20.58%    67,020       37.49%    -30,235      -36     
  LXU     $-1.010   -0.12%    631,742      35.56%    739,601      41.63%    -107,859     -1,068  
  ALNY    $-34.090  -0.49%    5,997,915    35.92%    6,409,433    38.38%    -411,518     -121    
  IDRA    $-0.430   -0.17%    928,518      36.00%    1,105,281    42.85%    -176,763     -4,111  
  HCI     $-3.650   -0.13%    224,493      29.93%    245,573      32.74%    -21,080      -58     
  NVFY    $-0.610   -0.15%    155,139      27.47%    238,372      42.21%    -83,233      -1,364  

For example, the chart above shows ATRO with a dollar loss Thursday of $-8.34000 and a Friction Factor of -36 shares. That means that it only took 36 more shares of selling than buying to move ATRO lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

Astronics Corporation (NASDAQ:ATRO) - Astronics Corporation, through its subsidiaries, designs and manufactures products for the aerospace, defense, electronics, and semiconductor industries worldwide. It operates in two segments, Aerospace and Test Systems. The Aerospace segment offers lighting and safety systems; electrical power generation, distribution, and motions systems; aircraft structures; avionics products; and system certification and other products. This segment serves airframe manufacturers (OEM) that build aircraft for the commercial, military, and general aviation markets; suppliers; and aircraft operators, such as airlines and branches of the U.S. Department of Defense, as well as the Federal Aviation Administration and airport operators. The Test Systems segment designs, develops, manufactures, and maintains automatic test systems that support the semiconductor, aerospace, communications, and weapons test systems, as well as training and simulation devices for commercial and military applications. It serves OEMs and prime government contractors for consumer electronics and military products. The company also provides engineered commercial aerospace interior components and systems for the aerospace industry; fuselage and tail-mounted antenna systems for commercial transport, business jet, and military aircraft; in-flight entertainment/communication systems and cabin management systems for private aircraft; and engineering, design, and certification solutions for commercial aircraft. Astronics Corporation was founded in 1968 and is headquartered in East Aurora, New York..

LSB Industries, Inc. (NYSE:LXU) - LSB Industries, Inc., through its subsidiaries, manufactures and sells chemical products, water source and geothermal heat pumps, and air handling products in the United States and internationally. It operates through two segments, Chemical Business and Climate Control Business. The Chemical Business segment manufactures and sells nitrogen-based chemical products, including ammonia, fertilizer grade ammonium nitrate (AN), urea ammonia nitrate, and AN ammonia solution for agricultural applications; high purity and commercial grade ammonia, high purity AN, sulfuric acids, concentrated, blended and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN and solutions for the mining industry. It offers industrial acids and other chemical products to the polyurethane, paper, fibers, emission control, and electronics industries; and blended and regular nitric acid, and industrial and high purity ammonia for various specialty applications, including the reduction of air emissions from power plants. This segment also offers its agricultural products to farmers, ranchers, fertilizer dealers, and distributors. The Climate Control Business segment manufactures and sells various heating, ventilation, and air conditioning products, such as water source and geothermal heat pumps; hydronic fan coils; and other HVAC products, including large custom air handlers, modular geothermal, air and water cooled chillers, and other products and services for use in commercial/institutional and residential new building construction, renovation of existing buildings, and replacement of existing systems. This segment primarily serves original equipment manufacturers, contractors, and independent sales representatives. The company also sells industrial machinery and related components to machine tool dealers and end users. LSB Industries, Inc. was founded in 1968 and is headquartered in Oklahoma City, Oklahoma..

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an investigational RNAi therapeutic that is in Phase I clinical trial for the treatment of hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-AS1 for the treatment of hepatic porphyrias. Its product development programs also include ALN-AAT for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia; ALN-HBV for the treatment of Hepatitis B virus; ALN-AC3 for the treatment of hypertriglyceridemia; ANGPTL3 for the treatment of hypertriglyceridemia and mixed hyperlipidemia; ALN-AGT for the treatment of hypertensive disorders of pregnancy, including preeclampsia; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-HDV for the treatment of HDV infection; and ALN-PDL for the treatment of chronic liver infections. The company has strategic alliances and collaboration agreements with Ionis Pharmaceuticals, Inc.; Novartis Pharma AG; Novartis/Arrowhead; F. Hoffmann-La Roche Ltd; Roche/Arrowhead; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; Ascletis BioScience Co., Ltd.; Monsanto Company; Sanofi Genzyme; The Medicines Company; Arbutus Biopharma Corporation; Protiva Biotherapeutics, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts..

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) - Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The company s lead drug candidate is IMO-8400, which is in Phase I/II clinical trials for the treatment of Waldenstr m s Macroglobulinemia and diffuse large B-cell lymphoma, as well as in Phase II clinical trial for the treatment of dermatomyositis. Its drug candidates also comprise IMO-9200, a drug candidate in Phase I clinical trial for use in selected autoimmune disease indications; and IMO-2055/IMO-2125 that are in Phase I/II clinical trials for applications as immune therapies for the treatment of cancer. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. It has license and research collaboration agreement with Merck & Co. to research, develop, and commercialize vaccine products containing TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimer s disease; an agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test; a collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts..

Homecapital Investment Corp (NYSE:HCI) - .

Nova Lifestyle Inc. (NASDAQ:NVFY) - .

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net